Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90.

17-Allylamino-17-demethoxygeldanamycin (17-AAG)1 is a semisynthetic inhibitor of the 90 kDa heat shock protein (Hsp90) currently in clinical trials for the treatment of cancer. However, 17-AAG faces challenging formulation issues due to its poor solubility. Here we report the synthesis and evaluation of a highly soluble hydroquinone hydrochloride derivative of 17-AAG, 1a (IPI-504), and several of the physiological metabolites. These compounds show comparable binding affinity to human Hsp90 and its endoplasmic reticulum (ER) homologue, the 94 kDa glucose regulated protein (Grp94). Furthermore, the compounds inhibit the growth of the human cancer cell lines SKBR3 and SKOV3, which overexpress Hsp90 client protein Her2, and cause down-regulation of Her2 as well as induction of Hsp70 consistent with Hsp90 inhibition. There is a clear correlation between the measured binding affinity of the compounds and their cellular activities. Upon the basis of its potent activity against Hsp90 and a significant improvement in solubility, 1a is currently under evaluation in Phase I clinical trials for cancer.

[1]  B. Blagg,et al.  Radanamycin, a macrocyclic chimera of radicicol and geldanamycin. , 2006, Bioorganic & medicinal chemistry letters.

[2]  S. Jagannath,et al.  Update on Phase I Clinical Trial of IPI-504, a Novel, Water-Soluble Hsp90 Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM). , 2005 .

[3]  Yves L Janin,et al.  Heat shock protein 90 inhibitors. A text book example of medicinal chemistry? , 2005, Journal of medicinal chemistry.

[4]  David Siegel,et al.  Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition. , 2005, Cancer research.

[5]  R. Immormino,et al.  Structure of Unliganded GRP94, the Endoplasmic Reticulum Hsp90 , 2005, Journal of Biological Chemistry.

[6]  A. Lowell,et al.  Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins. , 2005, Cancer research.

[7]  S. Lakhani,et al.  Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Xavier Barril,et al.  Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design. , 2005, Journal of medicinal chemistry.

[9]  P. Richardson,et al.  Dose escalating trial of 17-AAG with bortezomib (BZ) in patients with relapsed refractory multiple myeloma (MM) , 2005 .

[10]  Kedar Patel,et al.  Engineered biosynthesis of geldanamycin analogs for Hsp90 inhibition. , 2004, Chemistry & biology.

[11]  S. Jackson,et al.  Independent ATPase activity of Hsp90 subunits creates a flexible assembly platform. , 2004, Journal of molecular biology.

[12]  R. Immormino,et al.  Ligand-induced Conformational Shift in the N-terminal Domain of GRP94, an Hsp90 Chaperone* , 2004, Journal of Biological Chemistry.

[13]  D. Solit,et al.  Hsp90: the vulnerable chaperone. , 2004, Drug discovery today.

[14]  Yaoquan Liu,et al.  Synthesis and biological activities of novel 17-aminogeldanamycin derivatives. , 2004, Bioorganic & medicinal chemistry.

[15]  T. Isobe,et al.  IC101 Induces Apoptosis by Akt Dephosphorylation via an Inhibition of Heat Shock Protein 90-ATP Binding Activity Accompanied by Preventing the Interaction with Akt in L1210 Cells , 2004, Journal of Pharmacology and Experimental Therapeutics.

[16]  N. Rosen,et al.  Development of a Fluorescence Polarization Assay for the Molecular Chaperone Hsp90 , 2004, Journal of biomolecular screening.

[17]  L. Whitesell,et al.  Altered Hsp90 function in cancer: a unique therapeutic opportunity. , 2004, Molecular cancer therapeutics.

[18]  A. Kamal,et al.  Synthesis and biological evaluation of a new class of geldanamycin derivatives as potent inhibitors of Hsp90. , 2004, Journal of Medicinal Chemistry.

[19]  S. Larson,et al.  Phase 1 pharmacokinetic and pharmacodynamic trial of docetaxel and 17AAG (17-allylamino-17-demethoxygeldanamycin). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  L. Neckers,et al.  Quantum chemical calculations and mutational analysis suggest heat shock protein 90 catalyzes trans-cis isomerization of geldanamycin. , 2004, Chemistry & biology.

[21]  N. Rosen,et al.  Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90. , 2004, Chemistry & biology.

[22]  P. Workman.  Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone. , 2004, Cancer letters.

[23]  P. Csermely,et al.  Inhibition of Hsp90: a new strategy for inhibiting protein kinases. , 2004, Biochimica et biophysica acta.

[24]  W. Stolz,et al.  Induction of Hsp90 protein expression in malignant melanomas and melanoma metastases , 2004, Experimental dermatology.

[25]  L. Müller,et al.  Hsp70 and Hsp90--a relay team for protein folding. , 2004, Reviews of physiology, biochemistry and pharmacology.

[26]  C. Nicchitta,et al.  Structure of the N-terminal Domain of GRP94 , 2003, Journal of Biological Chemistry.

[27]  N. Rosen,et al.  Synthesis of novel fluorescent probes for the molecular chaperone Hsp90. , 2003, Bioorganic & medicinal chemistry letters.

[28]  L. Fritz,et al.  A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors , 2003, Nature.

[29]  L. Neckers,et al.  Cancer: The rules of attraction , 2003, Nature.

[30]  Andreas Schirmer,et al.  Filter binding assay for the geldanamycin-heat shock protein 90 interaction. , 2003, Analytical biochemistry.

[31]  Giulio Rastelli,et al.  Crystal structure and molecular modeling of 17-DMAG in complex with human Hsp90. , 2003, Chemistry & biology.

[32]  L. Neckers,et al.  Heat shock protein 90 as a molecular target for cancer therapeutics. , 2003, Cancer cell.

[33]  Gabriela Chiosis,et al.  BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. , 2002, Blood.

[34]  N. Rosen,et al.  Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathway. , 2002, Cancer research.

[35]  Sung Gyoo Park,et al.  Proteome analysis of hepatocellular carcinoma. , 2002, Biochemical and biophysical research communications.

[36]  B. Seed,et al.  Endoplasmic reticulum chaperone gp96 is required for innate immunity but not cell viability , 2001, Nature Cell Biology.

[37]  K. Bhalla,et al.  Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts. , 2001, Cancer research.

[38]  N. Rosen,et al.  A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells. , 2001, Chemistry & biology.

[39]  J. Peyrat,et al.  Proteomic detection of changes in protein synthesis induced by fibroblast growth factor-2 in MCF-7 human breast cancer cells. , 2001, Experimental cell research.

[40]  P. Sale,et al.  Heat shock protein-90, IL-6 and IL-10 in bladder cancer. , 2000, Anticancer Research.

[41]  C. Nicchitta,et al.  Ligand Interactions in the Adenosine Nucleotide-binding Domain of the Hsp90 Chaperone, GRP94 , 2000, The Journal of Biological Chemistry.

[42]  L. Neckers,et al.  The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. , 2000, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[43]  Y. Moriyama,et al.  Overexpression and localization of heat shock proteins mRNA in pancreatic carcinoma. , 2000, Journal of Nippon Medical School = Nippon Ika Daigaku zasshi.

[44]  L. Pearl,et al.  Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. , 1999, Journal of medicinal chemistry.

[45]  M. Egorin,et al.  Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations. , 1998, Cancer research.

[46]  M. Galigniana,et al.  The Role of DnaJ-like Proteins in Glucocorticoid Receptor·hsp90 Heterocomplex Assembly by the Reconstituted hsp90·p60·hsp70 Foldosome Complex* , 1998, The Journal of Biological Chemistry.

[47]  L. Neckers,et al.  Geldanamycin-induced destabilization of Raf-1 involves the proteasome. , 1997, Biochemical and biophysical research communications.

[48]  L. Pearl,et al.  Identification and Structural Characterization of the ATP/ADP-Binding Site in the Hsp90 Molecular Chaperone , 1997, Cell.

[49]  P. Sutphin,et al.  Geldanamycin-stimulated destabilization of mutated p53 is mediated by the proteasome in vivo , 1997, Oncogene.

[50]  Neal Rosen,et al.  Crystal Structure of an Hsp90–Geldanamycin Complex: Targeting of a Protein Chaperone by an Antitumor Agent , 1997, Cell.

[51]  E. Alnemri,et al.  Nucleotides and Two Functional States of hsp90* , 1997, The Journal of Biological Chemistry.

[52]  P. Miller,et al.  erbB-2 oncogene inhibition by geldanamycin derivatives: synthesis, mechanism of action, and structure-activity relationships. , 1995, Journal of medicinal chemistry.

[53]  C. Diorio,et al.  Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives. , 1995, Journal of medicinal chemistry.

[54]  P. Rose,et al.  Analysis of heat‐shock protein expression in myeloid leukaemia cells by flow cytometry , 1995, British journal of haematology.

[55]  L. Neckers,et al.  Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[56]  M. Ferrarini,et al.  Unusual expression and localization of heat‐shock proteins in human tumor cells , 1992, International journal of cancer.

[57]  H. Nawata,et al.  High constitutive expression of heat shock protein 90α in human acute leukemia cells , 1992 .

[58]  R. Coombes,et al.  Clinical and biological significance of HSP89 alpha in human breast cancer , 1992, International journal of cancer.

[59]  B. Lai,et al.  Quantitation and intracellular localization of the 85K heat shock protein by using monoclonal and polyclonal antibodies , 1984, Molecular and cellular biology.

[60]  M. Muroi,et al.  Macbecins I and II, new antitumor antibiotics. II. Isolation and characterization. , 1980, The Journal of antibiotics.